



PROTECH

Factsheet

**European
Heterosexual
Cisgender
Women**

Inject PrEP to protect?

The first Pan European study exploring the willingness to use long-acting injectable PrEP to prevent HIV.



Maastricht University

What is the PROTECT Survey?

This online survey was conducted across Europe (Oct 2023 to March 2024) and sought to uncover who may benefit from the innovation that is long-acting injectable PrEP.

The European Commission (EC) has authorized Apretude ® (cabotegravir long-acting [LA] injectable and tablets) for HIV prevention.


It is important for health services and policy makers to understand who may be interested in taking long-acting injectable PrEP so that resources can be most effectively allocated.

This factsheet reports on data from the PROTECT Survey collected from European Heterosexual Cisgender Women, who report being HIV-negative, N= 2413.


Heterosexual Cisgender Women

2413

SURVEYS COLLECTED BY COUNTRY




AGE




Heterosexual Cisgender Women

2413

MIGRANT STATUS



RELATIONSHIP STATUS




A good representation of heterosexual cisgender women in Europe




Heterosexual Cisgender Women **2413**

CHEMSEX (in the past 6 months)



NUMBER OF SEXUAL PARTNERS (in the past 6 months)




Heterosexual Cisgender Women

2413

Example of campaign image



HIV TESTING FREQUENCY



- More than every 6 months: 17
- Every 6 months: 61
- Less than once a year: 0
- Once a year: 235
- Never: 2100

ORAL PrEP USE HISTORY & CURRENT PrEP REGIMEN


- Naive: 2409
- Current: 1
- Former: 3

Naive: 2409

Heterosexual Cisgender Women

2413

AWARENESS OF ORAL PrEP



Example of campaign image



Barriers to oral PrEP use

- **1% of the heterosexual cisgender women said:**
 - Oral PrEP was too costly (either the pills or the tests associated with PrEP use)
- **2% of the heterosexual cisgender women said :**
 - Their healthcare provider did not offer oral PrEP to them
- **0.4% of the heterosexual cisgender women said:**
 - There was a waiting list at their healthcare provider for oral PrEP and the service was not available
- **0.4% of the heterosexual cisgender women said:**
 - The procedure took too long to obtain oral PrEP when they needed it




Long-acting PrEP: interest and intention

13%

are interested in using LA-PrEP if it becomes available.*

9%

intend to use LA-PrEP if it becomes available.*



Summary & Contact Information

SUMMARY

- Few heterosexual cisgender women across Europe are aware of PrEP and have taken up oral PrEP. Barriers to starting PrEP still exist.
- Interest and intention to use LA-PrEP among heterosexual cisgender women across Europe is low and gaps exist between interest to use LA-PrEP and current oral PrEP use.
- LA-PrEP may provide an opportunity for greater HIV prevention in Europe

CONTACT INFORMATION

- Prof. Dr. Kai J. Jonas
Email: kai.jonas@maastrichtuniversity.nl
- Dr. Johann Kolstee
Email:
johann.kolstee@maastrichtuniversity.nl
- Maastricht University postal address
P.O. Box 616, 6200 MD Maastricht, The Netherlands